Avastin alterations
November 21, 2011
THE US Food and Drug Authority
has revoked Avastin’s breast cancer
indication, saying it has not been
shown to be safe and effective for
that use.
“After reviewing the available
studies it is clear that women who
take Avastin for metastatic breast
cancer risk potentially lifethreatening
side effects without
proof that the use of Avastin will
provide a benefit, in terms of delay
in tumor growth, that would justify
those risks,” the FDA said.
“Nor is there evidence that use of
Avastin will either help them live
longer or improve their quality of
life,” the FDA added.
The agency has however allayed
concerns, saying the drug will still
remain on the market as an approved
treatment for certain types of
colon, lung, kidney and brain
cancer (glioblastoma multiforme).
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Nov 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Nov 11
